IRF3 and neoplasm: 57% of tumour inhibition was observed in 4T1 murine mice model surpassing cisplatin efficacy (36%), activation of STING pathway leading to infiltration of IFN‐β, IL‐6 and IL‐12 in response to phosphorylation of TBK1 and IRF3. Prolonged survival and nearly completed tumour irradiation on combination with anti‐PD‐1 blocker